Replies to post #109941 on Biotech Values

[jq1234]

But I suspect the issue is still open. If a drug misses of a PR/CR type primary but CLEALRY hits on OS, it could get approved.

That's when the trial is powered to show OS, and pre-planned for alpha spending for secondary endpoints. Without that, once primary endpoint fails, then statistical significant secondary endpoint is nomimal.